Table 3 Treatment-emergent changes in blood pressure and pulse
From: A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine
Category | Galcanezumab 120Â mg | Galcanezumab 240Â mg | ||
|---|---|---|---|---|
N | n (%) | N | n (%) | |
Elevated BP and pulse | ||||
 Sitting SBP ≥140 mmHg and ≥ 20 mmHg increase from baseline | 120 | 5 (4.2) | 124 | 4 (3.2) |
 Sitting DBP ≥90 mmHg and ≥ 10 mmHg increase from baseline | 116 | 6 (5.2) | 126 | 16 (12.7)* |
 Sitting pulse > 100 bpm and ≥ 15 bpm increase from baseline | 129 | 3 (2.3) | 139 | 5 (3.6) |
Sustained elevation at 2 consecutive visits | ||||
 Sitting SBP | 119 | 1 (0.8) | 119 | 1 (0.8) |
 Sitting DBP | 115 | 2 (1.7) | 121 | 2 (1.7) |
 Sitting pulse | 128 | 0 | 133 | 3 (2.3) |
Potentially clinically significant elevation at anytime | ||||
 Sitting SBP ≥180 mmHg and ≥ 20 mmHg increase from baseline | 129 | 0 | 139 | 0 |
 Sitting DBP ≥105 mmHg and ≥ 15 mmHg increase from baseline | 129 | 1 (0.8) | 138 | 1 (0.7) |